Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 25Neoplasms 12Giant Cell Tumor of Bone 10Prostatic Neoplasms 9Multiple Myeloma 9Neoplasm Metastasis 8Osteoporosis 4Fractures, Bone 4Carcinoma, Non-Small-Cell Lung 4Recurrence 3Kidney Neoplasms 3Carcinoma, Renal Cell 3Bone Neoplasms 3Bone Diseases, Metabolic 3Bone Diseases 3Spinal Cord Compression 2Smoldering Multiple Myeloma 2Parathyroid Neoplasms 2Melanoma 2Lymphoma 2Lung Neoplasms 2Giant Cell Tumors 2Bone Metastases 2Bone Cysts, Aneurysmal 2With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer Metastatic 1Paraproteinemias 1

Interventions

Denosumab 2radium Ra 223 dichloride 1Radiotherapy 1Radiation 1QL1206 1Magnetic Resonance Spectroscopy 1Hydroxychloroquine 1Fentanyl 1Exercise 1Docetaxel 1Continuous Glucose Monitoring 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Bone Metastases × Denosumab × Clear all
NCT04812509 2023-02-24

Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 3 Completed
708 enrolled

Bone Metastases

NCT04550949 2020-09-22

To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

Qilu Pharmaceutical Co., Ltd.

Phase 3 Unknown
700 enrolled

Bone Metastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡